AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
The below mention stocks are part of Australiaâs biggest industry, i.e., Healthcare Industry. In the recent past, these healthcare stocks have made significant progress in their strategic objectives. Letâs take a closer look at these stocks-
HeraMED Limited (ASX:HMD)
HeraMED Limited (ASX:HMD) is a provider of innovative connected pregnancy monitoring solutions which also offers comprehensive hardware solutions supported by software applications, focused on fetal well-being and parental assurance.
In December 2018, the company successfully completed its over-subscribed $6 million IPO on the ASX, proceeds of which will be used to accelerate the commercialization of the Companyâs proprietary HeraBEAT device which is a smart, medical grade, home pregnancy monitoring solution. Earlier in November 2018, the companyâs HeraBEAT device received TGA (Therapeutic Goods Administration) approval to expedite its launch into the Australian market.
For the half year ended 30 June 2018, the company had current assets of US$2,025K and total current liabilities of US$2,256K. The total comprehensive loss for the half year ended 30 June 2018 was US$599k with basic and diluted loss per share of US$5.99.
The company has signed a comprehensive distribution agreement with Australiaâs leading baby and toddler product supplier, Dale Group International to distribute a minimum of 9k units over the first three years, generating a minimum of approximately AU$1.9 Mn over the first three years. The company is rapidly expanding its distribution network across several countries as well as progressing opportunities with major healthcare providers.
The company was listed on ASX on 12 December 2018, and it is currently traded at $0.180 with a market capitalization of circa $17.25 million as on 14 January 2019.
Mesoblast Limited (ASX:MSB)
Leading developer of innovative cellular medicines, Mesoblast Limited (ASX:MSB) today (14 January 2019) announced that it has drawn down US$15mn from its US$75mn, non-dilutive, credit facility of 4 years with Hercules Capital, Inc., proceeds of which will be used to ramp up the companyâs product commercialization programs. As per the announcement, the company could draw an additional US$25mn from the Hercules facility in the fourth quarter of 2019.
During the first half of 2019, the company is planning to meet with the US FDA (Food and Drug Administration) to discuss a potential approval pathway for its product candidate Revascor which has recently received clinically meaningful outcome during trials. Recently, the company completed the patient recruitment of Revascor (MPC-150-IM) Phase 3 trial which was a significant step forward in the companyâs target of bringing an effective therapy for the treatment of patients with progressive heart failure, and a significant commercial opportunity for the company. If the third phase trial confirms the results of the previous trails, Revascor will become a powerful treatment method for advanced heart failure.
In the last six months, the share price of Mesoblast limited decreased by 13.27 percent as on 11 January 2019. MSBâs shares traded at $1.310 ( -2.239% intraday) with a market capitalization of circa $668.16 million as on 14 January 2019.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
